Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

This research study is being conducted to evaluate the feasibility of prescribing oral vancomycin in preventing CDI in patients who are receiving concomitant systemic antibiotics.

There are two groups: one group will receive oral vancomycin 125 mg twice daily for the duration of systemic antibiotic use plus two additional days; the other group will receive the current standard of care which is no oral vancomycin. The investigators aim to collect data from 100 patients in each group for a total of 200 patients.

Eligible participants will be randomized in a 1:1 ratio to receive either oral vancomycin or no oral vancomycin. A computer-generated randomization sequence has been created using block randomization with variable block sizes (4, 6, 8) to maintain group balance and reduce predictability.

Inclusion criteria

• Age 65 years or older
• Receive systemic antibiotics in the last 90 days
• Hospitalized anywhere in the last 90 days
• History of C diff colonization without history of C diff colitis (infection)
• Provide informed consent
• Read and understand the English language
• Not current taking probiotics
• Lack of allergy or contraindications to receive vancomycin
• Ability to take oral medications
• Not receiving medications that can be used to treat or prevent C diff

Exclusion criteria

• Age 64 years or younger
• Has not received systemic antibiotics in the last 90 days
• Has not been hospitalized in the last 90 days
• History of C diff colonization with a history of C diff colitis (infection)
• Not provided informed consent
• Cannot read and understand the English language
• Currently receiving probiotics
• Allergy or contraindications to receive vancomycin
• Unable to take oral medications
• Receiving medications that can be used to treat or prevent C diff